© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First
March 22, 2024
CMS says Medicare Part D plans will cover semaglutide for individuals with overweight/obesity who have preexisting CVD, a first after 40 years of legal prohibition.
Next-Generation Cologuard Surpasses FIT for Colorectal Cancer Detection in Pivotal BLUE-C Trial
March 21, 2024
Cologuard Plus bests previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.
Long COVID's Long Road: The Muddled Map at 4 Years
March 21, 2024
Long COVID affects approximately 20 million people in the US and that number may be conservative. Here, a snapshot, through the fog, of the route they are on.
Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings
March 20, 2024
LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.
FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision
March 20, 2024
Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.
COPD 10-Fold More Common in Adults with Asthma, Most Severe Comorbidity: Population-Based Study
March 19, 2024
Adults with asthma are at significantly increased risk for a range of comorbidities including COPD, rhinosinusitis, atopic dermatitis, and GERD that may affect disease management and cost of care.
Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data
March 19, 2024
The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.
Blood-Based DNA Test Shows Sensitivity of 83% for Colorectal Cancer
March 15, 2024
Findings from the ECLIPSE clinical trial showed the blood-based cancer screening test detects 83% of people with CRC, with a specificity of 90%.
Optinose Xhance approved by FDA as first medical therapy for CRS
March 15, 2024
Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.
Madrigal's Resmetirom Wins Historic FDA Approval for Noncirrhotic NASH
March 14, 2024
Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.